In:
International Journal of Cancer, Wiley, Vol. 147, No. 7 ( 2020-10), p. 1970-1978
Abstract:
What's new? Although sorafenib, a kinase inhibitor drug, is effective in the treatment of advanced liver cancer, a large fraction of patients discontinue treatment because of adverse events. Here the authors evaluated the effect of drug dosing on treatment outcome in a large cohort study in South Korea. They found that proper sorafenib dose reduction helped control adverse events, leading to increased patient adherence coupled with longer duration and ultimately improved patient survival. They propose that proper dose modifications are a key determinant of successful sorafenib treatment.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink